Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice | Zendy

Maxime Denis | Zendy; Jadwiga Marcinkiewicz | Zendy; Ahmed Zaid | Zendy; Dany Gauthier | Zendy; Steve Poirier | Zendy; Claude Lazure | Zendy; Nabil G. Seidah | Zendy; Annik Prat | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice

Author(s) -

Maxime Denis,

Jadwiga Marcinkiewicz,

Ahmed Zaid,

Dany Gauthier,

Steve Poirier,

Claude Lazure,

Nabil G. Seidah,

Annik Prat

Publication year - 2012

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.111.057406

Subject(s) - kexin , pcsk9 , medicine , endocrinology , proprotein convertase , apolipoprotein b , ldl receptor , cholesterol , lipoprotein , familial hypercholesterolemia , genetically modified mouse , knockout mouse , subtilisin , receptor , apolipoprotein e , transgene , chemistry , biochemistry , enzyme , gene , disease

The proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes independently of its enzymatic activity the degradation of the low-density lipoprotein (LDL) receptor. PCSK9 gain of function in humans leads to autosomal dominant hypercholesterolemia, whereas the absence of functional PCSK9 results in ≈7-fold lower levels of LDL cholesterol. This suggests that lowering PCSK9 may protect against atherosclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research